Impacts of anti-nerve growth factor antibody on pain-related behaviors and expressions of opioid receptor in spinal dorsal horn and dorsal root ganglia of rats with cancer-induced bone pain.
OBJECTIVE
To investigate the impacts of anti-nerve growth factor antibody on pain-related behaviors and expressions of μ-opioid receptor in spinal dorsal horn and dorsal root ganglia of rats with cancer-induced bone pain.


METHODS
The rats were randomly grouped and then injected with 10 μl of phosphate buffer saline or Walker256 tumor cells into the upper segment of left tibia. Thirteen days after the injection, the intrathecal catheterization was performed, followed by the injection of saline, anti-nerve growth factor, nerve growth factor, and naloxone twice a day. The pain ethological changes were measured at the set time points; the expression changes of μ-opioid receptor protein and mRNA in spinal dorsal horn and dorsal root ganglia were detected on the 18th day.


RESULTS
After the tumor cells were injected into the tibia, hyperalgesia appeared and the expression of μ-opioid receptor protein and mRNA in spinal dorsal horn and dorsal root ganglia was increased, compared with the sham group; after intrathecally injected anti-nerve growth factor, the significant antinociceptive effects appeared, and the μ-opioid receptor expression was increased, compared with the cancer pain group; the μ-opioid receptor expressions in the other groups showed no statistical significance. The naloxone pretreatment could mostly inverse the antinociception effects of anti-nerve growth factor.


CONCLUSIONS
Anti-nerve growth factor could reduce hyperalgesia in the cancer-induced bone pain rats, and the antinociceptive effects were related with the upregulation of μ-opioid receptor.
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China proyaopeng@163.com.
Peng
P
Yao
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Yuanyuan
Y
Ding
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Zhibin
Z
Wang
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Jiaming
J
Ma
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Tao
T
Hong
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Yongqiang
Y
Zhu
Department of Pain Management, Shengjing Hospital of China Medical University, Shenyang, China.
Hongxi
H
Li
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China.
Shinong
S
Pan
D000818:Animals; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects*; D015153:Blotting, Western; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D000072716:Cancer Pain / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005727:Ganglia, Spinal / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D020932:Nerve Growth Factor / Q000276:immunology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D060888:Real-Time Polymerase Chain Reaction; D017450:Receptors, Opioid, mu / Q000235:genetics* / Q000378:metabolism; D066148:Spinal Cord Dorsal Horn / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology
D000906:Antibodies; D012333:RNA, Messenger; D017450:Receptors, Opioid, mu; D020932:Nerve Growth Factor
Cancer-induced bone pain; intrathecal injection; nerve growth factor; opioid receptor; pain-related behaviors